Cited by — Measurable residual disease-negative remission of BRAF-V600Emutated acute myeloid leukemia with dabrafenib and trametinib | ResearchHub - ResearchHub
Research graph
Cited by
Admitted local publications that cite Measurable residual disease-negative remission of BRAF-V600Emutated acute myeloid leukemia with dabrafenib and trametinib.
No admitted local citation edges point to this work yet.
